Torben Plesner

Søgeresultater

• 2015

  Road-maptoa prospective assessment of frailty in newly diagnosed myeloma patients

  Plesner, T., Broch, B., Corradini, A., Andersen, K. & Axelsen, L., 2015, I: Supportive Care in Cancer. 23, S1, s. S98 1 s., 08-09-P.

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

  Åben adgang

• Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages

  Andersen, K. T., Hinge, M., Segel, E. K., Ormstrup, T., Holdgaard, P., Boel-Jørgensen, H., Pallisgaard, N., Kerndrup, G. B. & Plesner, T., sep. 2015, I: Clinical Lymphoma Myeloma and Leukemia. 15, Supplement 3, s. e144 1 s., PO-112.

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

• Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112

  Andersen, K. T., Hinge, M., Segel, E. K., Ormstrup, T., Holdgaard, P., Boel-Jørgensen, H., Pallisgaard, N., Kerndrup, G. B. & Plesner, T., sep. 2015.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review

• Selvskabte plager? Vi har et fantastisk godt offentligt sygehusvæsen. Men det må hellere forblive en hemmelighed.

  Plesner, T., 24. nov. 2015

  Publikation: Andet › Udgivelser på nettet - Net-publikation › Formidling

• Smouldering multiple myeloma risk factors for progression. An analysis of 289 cases in the danish multiple myeloma registry

  Sørrig, R., Klausen, T. W., Frølund, U. C., Gregersen, H., Helleberg, C., L. Kristensen, D., Andersen, N. F., Plesner, T., Pulczinsky, S., Albildgaard, N., Mourits-Andersen, T., Clausen, N. T., Vangsted, A., Salomo, M. & Gimsing, P., 2015.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Stasiagentens gyldne efterår: Ingen trivialitet er for lille til at undgå omhyggelig observation og registrering i en computer markeret af et veltrænet personale ved et klik med en mus.

  Plesner, T., 13. okt. 2015

  Publikation: Andet › Udgivelser på nettet - Net-publikation › Formidling

• Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

  Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L. & Brun, N. & 1 flere, Richardson, P. G., 24. sep. 2015, I: The New England Journal of Medicine. 373, 13, s. 1207-1219

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Myeloma 100%
  • Monotherapy 100%
  • Daratumumab 100%
  • CD38 100%
  • Disease 60%
• 2014

  An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma

  Mellqvist, U.-H., Paba-Prada, C., Palumbo, A., Plesner, T., Sonneveld, P., Voorhees, P., Byrne, C., Harmenberg, J., Nordström, E. & Richardson, P., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

  Paba-Prada, C., Palumbo, A., Mellqvist, U.-H., Voorhees, P., Plesner, T., Sonneveld, P., Byrne, C., Harmenberg, J., Nordstrom, E. & Richardson, P., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)

  Lokhorst, H. M., Laubach, J., Nahi, H., Plesner, T., Gimsing, P., Hansson, M., Minnema, M., Lassen, U. N., Krejcik, J., Ahmadi, T., Lisby, S., Basse, L., C. Brun, N. & Richardson, P. G., 2014, I: Journal of Clinical Oncology. 32, 15. Suppl., s. 8513-8513 1 s.

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

• Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)

  Lokhorst, H., Laubach, J., Nahi, H., Plesner, T., Gimsing, P., Hansson, M., Minnema, M., Lassen, U., Krejcik, J., Ahmadi, T., Khan, I., Uhlar, C., Lisby, S., Basse, L., C. Brun, N. & Richardson, P., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)

  Lokhorst, H., Laubach, J., Nahi, H., Plesner, T., Gimsing, P., Hansson, M., Minnema, M., Lassen, U. N., Krejcik, J., Ahmadi, T., Lisby, S., Basse, L., C. Brun, N. & Richardson, P., 20. maj 2014, I: Journal of Clinical Oncology. 32, 15 (Suppl.), 8513.

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

• Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer

  Søe, K., Delaissé, J.-M., Jakobsen, E. H., Hansen, C. & Plesner, T., 2014, I: Acta Oncologica. 53, 4, s. 547-556

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Creatinine 100%
  • Multiple Myeloma 100%
  • Zoledronic Acid 100%
  • Metastatic Breast Cancer 100%
  • Breast Cancer 33%

• Effects of single-agent bortezomib (btz) as post-transplant consolidation on multiple myeloma (MM)-related bone disease: first results from a multicenter, randomized phase 2 study

  Sezer, O., Beksac, M., Hajek, R., Sucak, G., Cagirgan, S., Linkesch, W., Meltem Akay, O., Armbrecht, G., Plesner, T., Snowden, J., Nahi, H., Gülbas, Z., Potamianou, A., Couturier, C., Olie, R., Feys, C., Allietta, N. & Terpos, E., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• European perspective on multiple myeloma treatment strategies in 2014

  Ludwig, H., Sonneveld, P., Davies, F., Bladé, J., Boccadoro, M., Cavo, M., Morgan, G., de la Rubia, J., Delforge, M., Dimopoulos, M., Einsele, H., Facon, T., Goldschmidt, H., Moreau, P., Nahi, H., Plesner, T., San-Miguel, J., Hajek, R., Sondergeld, P. & Palumbo, A., 2014, I: Oncologist. 19, 8, s. 829-844

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Myeloma 100%
  • Autologous Stem Cell Transplantation 100%
  • Remission 100%
  • Medicine 50%
  • Frailty 50%

• Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

  Eichhorst, B., Fink, A. M., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., G Kiehl, M., Soekler, M., Schlag, R., Vehling-Kaiser, U., R. A. Köchling, G., Plöger, C., Gregor, M., Plesner, T., Trneny, M., Fischer, K., Döhner, H., Kneba, M. & Wendtner, C.-M. & 5 flere, Klapper, W., Kreuzer, K. A., Stilgenbauer, S., Böttcher, S. & Hallek, M., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

  Zweegman, S., van der Holt, B., Mellqvist, U.-H., Salomo, M., M. J. Bos, G., Levin, M.-D., A. Visser-Wisselaar, H., Hansson, M., WG van der Velden, A., Deenik, W., Gruber, A., LLM Coenen, J., Plesner, T., K Klein, S., Tanis, B., L. Szatkowski, D., Brouwer, R., Westerman, M., Leys, B. & W. C. J. van de Donk, N. & 8 flere, Haukås, E., van der Hem, K., Durian, M., Mattijssen, E. J., AM Sinnige, H., JPL Stevens-Kroef, M., Sonneveld, P. & Waage, A., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

  Plesner, T., Arkenau, H.-T., Lokhorst, H. M., Gimsing, P., Krejcik, J., Rose Lemech, C., Minnema, M., Lassen, U. N., Laubach, J., Ahmadi, T., Yeh, H., Guckert, M., Feng, H., C. Brun, N., Lisby, S., Basse, L., Palumbo, A. & Richardson, P., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma

  Plesner, T., Arkenau, H.-T., Lokhorst, H. M., Gimsing, P., Krejcik, J., Rose Lemech, C., Minnema, M., Lassen, U. N., Ahmadi, T., Yeh, H., Guckert, M., C. Brun, N., Lisby, S., Basse, L., Palumbo, A. & Richardson, P., 2014.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review

• Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma

  Plesner, T., Arkenau, H.-T., Lokhorst, H. M., Gimsing, P., Krejcik, J., Rose Lemech, C., Minnema, M., Lassen, U. N., Ahmadi, T., Yeh, H., Guckert, M., C. Brun, N., Lisby, S., Basse, L., Palumbo, A. & Richardson, P. G., 2014, I: Journal of Clinical Oncology. 32, 15, 8533.

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Formidling

• Safety and efficacy of daraturmumab with lenalidomide and dexamethasone in relapsed or relapsed, refactory multiple myeloma

  Plesner, T., Arkenau, H.-T., Lokhorst, H. M., Gimsing, P., Krejcik, J., Rose Lemech, C., Minnema, M., Lassen, U. N., Laubach, J., Ahmadi, T., Yeh, H., Guckert, M., Feng, H., C. Brun, N., Lisby, S., Basse, L., Palumbo, A. & Richardson, P. G., 2014, I: Journal of Clinical Oncology. 124, 21

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

• The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

  van de Donk, N. W. C. J., Palumbo, A., Johnsen, H. E., Engelhardt, M., Gay, F., Gregersen, H., Hajek, R., Kleber, M., Ludwig, H., Morgan, G., Musto, P., Plesner, T., Sezer, O., Terpos, E., Waage, A., Zweegman, S., Einsele, H., Sonneveld, P., Lokhorst, H. M. & European Myeloma Network, jun. 2014, I: Haematologica. 99, 6, s. 984-996

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Disease 100%
  • Myeloma 100%
  • Monoclonal Gammopathy of Undetermined Significance 100%
  • Light Chain 33%
  • Multiple Myeloma 22%
• 2013

  A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

  Plesner, T., 1. nov. 2013, I: British Journal of Haematology. 163, 3, s. 334-342

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Diffuse Large B-Cell Lymphoma 100%
  • Monotherapy 100%
  • Phase II Trials 100%
  • Ofatumumab 100%
  • Diffuse Large B Cell Lymphoma 100%

• A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

  Popat, R., Plesner, T., Davies, F., Cook, G., Cook, M., Elliott, P., Jacobson, E., Gumbleton, T., Oakervee, H. & Cavenagh, J., 1. mar. 2013, I: British Journal of Haematology. 160, 5, s. 714-717

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

• A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia

  Birgens, H. S., Frederiksen, H., Hasselbalch, H. C., Rasmussen, I. H., Nielsen, O., Kjeldsen, L., Larsen, H., Mourits-Andersen, T., Plesner, T., Rønnov-Jessen, D., Vestergaard, H., Klausen, T. W. & Schöllkopf, C., nov. 2013, I: British Journal of Haematology. 163, 3, s. 393-399 7 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Glucocorticoid 100%
  • Prednisolone 100%
  • Monotherapy 100%
  • Rituximab 100%
  • Autoimmune Hemolytic Anemia 100%

• Bone Disease in Multiple Myeloma

  Hinge, M., Lund, T., Delaissé, J.-M. & Plesner, T., 2013, Multiple Myeloma: A Quick Reflection on the Fast Progress. Hajek, R. (red.). InTech - Open Access Publisher

  Publikation: Kapitel i bog/rapport/konference-proceeding › Kapitel i bog › Forskning

• Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

  CLL Study Group, dec. 2013.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: Preliminary efficacy data from a multicenter phase I/II study

  Lokhorst, H., Plesner, T., Gimsing, P., Nahi, H., Minnema, M., Lassen, U. N., Krejcik, J., Laubach, J., Lisby, S., Basse, L. & Richardson, P., maj 2013.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Daratumumab, a CD38 Monoclonal Antibody in Patients With Multiple Myeloma - Data From A Dose-Escalation Phase I/II Study

  Plesner, T., Lokhorst, H., Gimsing, P., Nahi, H., Basse, L., Lisby, S. & Richardson, P., apr. 2013.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Daratumumab, a CD38 Monoclonal Antibody Study in Advanced Multiple Myeloma – an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-Arm Phase I/II Study

  Lokhorst, H., Plesner, T., Gimsing, P., Nahi, H., Lisby, S. & Richardson, P., jun. 2013.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Daratumumab:Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma

  Richardson, P., Lokhorst, H., Palumbo, A., Nahi, H., Laubach, J., Gimsing, P., Lisby, S., Cakana, A., Brun, N. & Plesner, T., 2013, I: Drugs of the Future. 38, 8, s. 545-554

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Monoclonal Antibody 100%
  • Multiple Myeloma 100%
  • CD38 100%
  • Daratumumab 100%
  • Complement Dependent Cytotoxicity 42%

• Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?

  Søe, K., Plesner, T., Jakobsen, E. H., Hansen, C. T., Jørgensen, H. B. & Delaissé, J.-M., aug. 2013, I: Journal of Bone and Mineral Research. 28, 8, s. 1738-1750

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Breast Cancer 100%
  • Zoledronic Acid 100%
  • Bone Metastasis 100%
  • Multiple Myeloma 100%
  • Alkaline Phosphatase 100%

• Preliminary Safety and Efficacy Data of Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  GEN503 Study Group, dec. 2013.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Rituximab and Dexamethasone vs Dexamethasone Monotherapy in Newly Diagnosed Patients with Primary Immune Thrombocytopenia

  Gudbrandsdottir, S., Birgens, H. S., Frederiksen, H., Jensen, B. A., Jensen, M. K., Kjeldsen, L., Klausen, T. W., Larsen, H., Mourits-Andersen, H. T., Nielsen, C. H., Nielsen, O. J., Plesner, T., Pulczynski, S., Rasmussen, I. H., Rønnov-Jessen, D. & Hasselbalch, H. C., 14. mar. 2013, I: Blood. 121, 11, s. 1976-1981

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Dexamethasone 100%
  • Rituximab 100%
  • Idiopathic Thrombocytopenic Purpura 100%
  • Platelet 18%
  • Platelet Count 9%
• 2012

  A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma Preliminary Safety Data

  Gimsing, P., Plesner, T., Nahi, H., Lokhorst, H., Valentin, M.-L., Lisby, S. & Richardson, P., 2012, I: Blood. 118, 21, s. 1873 1 s.

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

• Continuous lenalidomide treatment for newly diagnosed multiple myeloma

  Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., Cascavilla, N., Iosava, G., Cavo, M., Kloczko, J., Bladé, J., Beksac, M., Spicka, I., Plesner, T., Radke, J. & Langer, C. & 8 flere, Ben Yehuda, D., Corso, A., Herbein, L., Yu, Z., Mei, J., Jacques, C., Dimopoulos, M. A. & MM-015 Investigators, 2012, I: The New England Journal of Medicine. 366, 19, s. 1759-69

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Myeloma 100%
  • Lenalidomide 100%
  • Prednisone 66%
  • Melphalan 66%
  • Placebo 16%

• Daratumumab, a CD38 Monoclonal Antibody in Patients with Mulitple Myeloma - Data From a Dose-Escalation Phase I/II Study

  Plesner, T., Lokhorst, H., Gimsing, P., Nahi, H., Lisby, S. & Richardson, P., 2012, I: Blood. 120, s. 73

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

• Daratumumab - a CD38 mAb - for the Treatment of relapsed/Refractory Multiple Myeloma Patients: Preliminary Efficacy Data from Multicenter Phase I/II Study

  Plesner, T., Lokhorst, H., Gimsing, P., Nahi, H., Lisby, S. & Richardson, P., 2012, I: Journal of Clinical Oncology. 30, Suppl., s. Abstr.8019

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning

• "Differences and similarities in treatment related effects of zoledronic acid in multiple myeloma and breast cancer patients with metastasis to bone." in Journal of Bone and Mineral Research, 27, suppl.1, p213-S214.

  Søe, K., Delaissé, J.-M., Hugger Jakobsen, E., Hansen, C. & Plesner, T., 2012. 2 s.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review

• "Differences and similarities in treatment related effects of zoledronic acid in multiple myeloma and breast cancer patients with metastasis to bone." in Journal of Bone and Mineral Research, 27, suppl.1, p213-S214.

  Søe, K., Delaissé, J.-M., Hugger Jakobsen, E., Hansen, C. & Plesner, T., 2012. 2 s.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• DMSG retningslinje 2012 for diagnostik og behandling af myelomatose

  Abildgaard , N., Gregersen, H., Andersen, N. F., Plesner, T., Pedersen, P. T., Gimsing, P., Clausen, N.-A. T., Vangsted, A. J. & Jensen, B. A., 2012, Myeloma.dk. 59 s.

  Publikation: Bog/rapport › Rapport › Forskning

• "Is zoledronic acid retention onto bone different in multiple myeloma and breast cancer patients with bone metastasis?" in Journal of Bone and Mineral Research, 27, suppl. 1, p323

  Søe, K., Plesner, T., Hugger Jakobsen, E., Hansen, C., Jørgensen, H. & Delaissé, J.-M., 2012. 1 s.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review

• "Is zoledronic acid retention onto bone different in multiple myeloma and breast cancer patients with bone metastasis?" in Journal of Bone and Mineral Research, 27, suppl. 1, p323

  Søe, K., Plesner, T., Hugger Jakobsen, E., Hansen, C., Jørgensen, H. & Delaissé, J.-M., 2012. 1 s.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• Paroxystisk Nokturn Hæmoglobinuri i Danmark

  Brieghel, C., Sørensen, L., Christiansen, I., Nielsen, B., Plesner, T., Vestergaard, H., Kræsten Raaschou Jensen, K., Klausen, T. W. & Birgens, H., 2012.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning

• Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase

  Haidl, F., Plesner, T. & Lund, T., 2012, I: Leukemia Research. 36, 10, s. 1296-1299

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Alkaline Phosphatase 100%
  • Multiple Myeloma 100%
  • Bortezomib 100%
  • Myeloma 33%
  • Zoledronic Acid 16%
• 2011

  Anti-myelin associated glycoprotein neuropathy responding to lenalidomide

  Larsen, L. H., Lund, T., Vilholm, O. J. & Plesner, T., 2011, I: Leukemia Research. 35, 11, s. e198-9

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

• A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015

  Palumbo, A., Adam, Z., Kropff, M., Foà, R., Catalano, J., Gisslinger, H., Wiktor-Jedrzejczak, W., Delforge, M., Weisel, K., Cascavilla, N., Van Droogenbroeck, J., Iosava, G., Cavo, M., Blade, J., Beksac, M., Spicka, I., Plesner, T., Yu, Z., Herbein, L. & Mei, J. & 2 flere, Jacques, C. & Dimopoulus, M., dec. 2011.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

• A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma Preliminary Safety Data

  Gimsing, P., Plesner, T., Nahi, H., Lokhorst, H., Valentin, M.-L., Lisby, S. & Richardson, P., 8. dec. 2011.

  Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review

• CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

  Pfreundschuh, M., Kuhnt, E., Trümper, L., Osterborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., Pettengell, R., Jaeger, U., Zinzani, P.-L., Shpilberg, O., Kvaloy, S., Brown, P. D. N., Stahel, R., Milpied, N., López-Guillermo, A., Poeschel, V., Grass, S. & Loeffler, M. & 3 flere, Murawski, N., MabThera International Trial (MInT) Group & Plesner, T., 2011, I: The Lancet Oncology (Czech Edition). 12, 11, s. 1013-1022

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Chemotherapy 100%
  • Rituximab 100%
  • Group Trial 100%
  • Diffuse Large B Cell Lymphoma 100%
  • B Cell 100%

• Inclusion of myeloma nuclei in osteoclasts activates their resorptive activity

  Kupisiewicz, K., Levin Andersen, T., Lund, T., Plesner, T., Kerndrup, G. B., Abildgaard , N., Preiss, B. S. & Delaissé, J.-M., 2011, I: Bone. 47, suppl 2, s. 295

  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review